福泰制药的镇痛药VX-993在II期临床试验中未能显著优于安慰剂,公司将终止其开发。Nav1.8抑制剂类镇痛药市场潜力巨大,但研发挑战重重。
Source Link福泰制药的镇痛药VX-993在II期临床试验中未能显著优于安慰剂,公司将终止其开发。Nav1.8抑制剂类镇痛药市场潜力巨大,但研发挑战重重。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.